Akebia Therapeutics Inc (STU:AX9)
€ 1.008 0.025 (2.54%) Market Cap: 213.24 Mil Enterprise Value: 214.06 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

Akebia Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 12:45PM GMT
David Neil Lebowitz
Morgan Stanley, Research Division - VP

(inaudible) registration desk. So I'd like to welcome to the stage with me from Akebia Therapeutics, CEO, John Butler. I'm one of the analysts here, David Lebowitz. Akebia's a fully integrated nephrology company, which has undergone some change in the last year, certainly with an integration. I guess before we really get started, could you just give a top level overview of the company and where it's come from and where it's going?

John P. Butler
Akebia Therapeutics, Inc. - CEO, President & Director

Sure, David. First, thanks so much for having us here today. As you said, Akebia is a fully integrated biopharma company that is focused on delivering innovative therapies for patients with kidney disease. And we have a commercial product now in Auryxia with 2 indications, hyperphosphatemia and iron deficiency anemia. And then we have our Phase III product, vadadustat, which is a hypoxia-inducible factor prolyl hydroxylase inhibitor, that's in development for treating the anemia of chronic kidney

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot